Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending December 6, 2002. The report details changes in directors' interests in the company's Ordinary Shares and American Depository Shares (ADSs) involving employee trusts.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on specific share transactions and trust activities rather than consolidated financial performance.
Material Changes
The report outlines specific transactions executed by trustees of the GlaxoSmithKline Employee Trust ("GSK Trust") and the GlaxoSmithKline (US) Trust ("GSK US Trust") between December 4 and December 5, 2002:
- Conversion and Sale: The GSK Trust converted 914,738 Ordinary Shares into 457,369 ADSs, which were subsequently sold at US$37.25 per ADS.
- Ordinary Share Sales: The GSK Trust sold 840 Ordinary Shares at £11.8535 per share and 3,318 Ordinary Shares at £11.9525 per share.
- Transfers: The GSK Trust transferred 14,695 Ordinary Shares to participants of the Glaxo Wellcome 1999 Long Term Incentive Plan.
- Purchase: The GSK US Trust purchased 457,369 ADSs at US$37.25 per ADS.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document serves as a disclosure of director interests and trust transactions.
Important Facts for Investors
- Directors Dr. J-P Garnier and John Coombe hold interests in the GSK Trust shares as potential beneficiaries alongside other employees.
- Director Dr. J-P Garnier holds an interest in the GSK US Trust shares as a potential beneficiary alongside former SmithKline Beecham employees.
- The transactions reported were advised to the company on December 6, 2002.
- No financial performance data is included in this specific filing.